ClinConnect ClinConnect Logo

Main Menu

Search for Trials
For HCPs
For Industry
Blog
Contact Us
Dark Mode
Log in Sign up
Search / Trial NCT00446485

Efficacy and Safety of Ginkgo Biloba Extract in Mild Cognitive Impairment and Cerebrovascular Insufficiency

Launched by MILSING D.O.O. · Mar 12, 2007

Download PDF Apply for Trial

Trial Information

Current as of April 24, 2025

Completed

Keywords

Ginkgo Biloba Cerebrovascular Insufficiency Mild Cognitive Impairment Concentration Impairment

ClinConnect Summary

Inclusion criteria is cerebrovascular insufficiency MNSE\>20. 90 patients are divided into three groups randomly. First group is being administered 120 mg ginkgo biloba extract, second group 60 mg of the extract and the third group has being administered placebo during the period of 6 months. Methods used for evaluation are SCAG, MMSE, MDRS, VFT, CGI, TCD and color Doppler of carotid arteries. Methods used for follow up safety include: routine blood tests, biochemical tests, neurologic and physical examination, vital signs and ECG.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • cerebrovascular insufficiency and mild cognitive disorder (MMSE=20-28)
  • Exclusion Criteria:
  • • pregnancy
  • • cognitive disorder caused by psychological, metabolic endocrine nutritional and heart disorder
  • • alcohol or drug abuse

Trial Officials

Vida Demarin, MD PHD

Principal Investigator

University Department of Neurology, Sestre milosrdnice University Hospital, Vinogradska 29, HR-10000 Zagreb, Croatia

About Milsing D.O.O.

milsing d.o.o. is a pioneering clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a strong commitment to ethical practices and regulatory compliance, milsing d.o.o. specializes in the design, management, and execution of clinical trials across various therapeutic areas. The organization collaborates closely with healthcare professionals, research institutions, and regulatory bodies to ensure the highest standards of quality and scientific integrity. By leveraging cutting-edge technology and a patient-centered approach, milsing d.o.o. aims to contribute significantly to the development of effective treatments and enhance the overall landscape of clinical research.

Locations

Zagreb, , Croatia

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials